Cediranib (AZD2171): ATP-Competitive VEGFR Tyrosine Kinase Inhibitor for Angiogenesis Inhibition

Executive Summary: Cediranib (AZD2171) is a highly potent, orally bioavailable ATP-competitive inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, with sub-nanomolar IC₅₀ values for VEGFR-2, making it one of the most selective angiogenesis inhibitors in preclinical research (Schwartz 2022). It also inhibits PDGFR-α/β, c-Kit, CSF-1R, and Flt-3, providing a broad yet mechanistically precise blockade of receptor tyrosine kinases. Cediranib blocks VEGF-induced phosphorylation of downstream effectors such as Akt (Ser473), disrupting PI3K/Akt/mTOR signaling and tumor angiogenesis (APExBIO). The compound is highly soluble in DMSO (≥22.52 mg/mL) but insoluble in water/ethanol, requiring -20°C storage for stability. APExBIO supplies Cediranib (A1882) for advanced in vitro and translational oncology workflows, with extensive characterization and workflow compatibility (ABT888.net).

Biological Rationale

Angiogenesis is a hallmark of cancer, driven primarily by VEGF signaling through VEGF receptors (VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4). Inhibition of these kinases disrupts vascular supply, starving tumors of nutrients and oxygen (Schwartz 2022). Cediranib targets these receptors with high affinity, directly impacting tumor microenvironment and progression. Its action enables dissection of angiogenic signaling in both proliferative and cytotoxic contexts. By also targeting PDGFRs and c-Kit, Cediranib provides a model for multi-pathway blockade, relevant in tumors exhibiting kinase redundancy.

Mechanism of Action of Cediranib (AZD2171)

Cediranib acts as an ATP-competitive inhibitor at the kinase domain of VEGFR-1, VEGFR-2, and VEGFR-3, with an IC₅₀ for VEGFR-2 of <1 nM under cell-free assay conditions (Schwartz 2022). It binds the ATP-binding site, blocking autophosphorylation and subsequent downstream signaling. Cediranib also inhibits PDGFR-α, PDGFR-β, c-Kit, CSF-1R, and Flt-3, though with variable potency (IC₅₀ 0.002–>1 μM). The inhibition of VEGFR-mediated phosphorylation prevents activation of PI3K/Akt/mTOR and other survival pathways, resulting in reduced angiogenesis and tumor growth (APExBIO).

Evidence & Benchmarks

• Cediranib exhibits <1 nM IC₅₀ for VEGFR-2 in cell-free kinase assays (Schwartz 2022, https://doi.org/10.13028/wced-4a32).
• Inhibits VEGF-induced phosphorylation of Akt (Ser473) in endothelial cell lines, measured by Western blot within 30–60 minutes post-treatment (Schwartz 2022, Fig. 4.6).
• Blocks angiogenic sprouting in 3D in vitro models at concentrations ≥5 nM, with no significant cytotoxicity to non-endothelial cells (Schwartz 2022, Fig. 5.3).
• Demonstrates broad kinase inhibition: IC₅₀ for PDGFR-β ≈ 5 nM, c-Kit ≈ 2 nM, Flt-3 ≈ 20 nM (APExBIO product data, https://www.apexbt.com/cediranib-azd217.html).
• Highly soluble in DMSO (≥22.52 mg/mL at 25°C), but insoluble in water or ethanol (APExBIO, https://www.apexbt.com/cediranib-azd217.html).

For advanced discussion of Cediranib’s mechanistic precision and its integration in translational workflows, see "Cediranib (AZD2171): Mechanistic Precision, Translational..." (this article extends the comparison to next-generation in vitro models and off-target profiling).

For a review of ATP-competitive VEGFR inhibitors in advanced modeling, "Cediranib (AZD2171): Advanced In Vitro Modeling for VEGFR..." provides additional context on workflow integration; this article clarifies Cediranib’s quantitative benchmarks and solubility parameters.

Applications, Limits & Misconceptions

Cediranib (AZD2171) is widely used for:

• In vitro studies of VEGFR-mediated signaling and angiogenesis inhibition.
• Dissection of the PI3K/Akt/mTOR axis in tumor and endothelial cells.
• Multi-target kinase inhibition in preclinical models of cancer.
• Tool compound for evaluating anti-angiogenic drug responses alongside viability and apoptosis markers (Schwartz 2022).

It is not suitable for routine in vivo administration in clinical settings; its use is restricted to preclinical and translational research (APExBIO).

Common Pitfalls or Misconceptions

• Cediranib is not selective for VEGFR alone; off-target inhibition of PDGFR and c-Kit can confound pathway analysis at higher concentrations.
• Compound is insoluble in water or ethanol; DMSO is required for stock solutions, and immediate use after dilution is recommended for stability.
• Long-term storage of Cediranib solutions at room temperature or 4°C leads to degradation; -20°C is required for the solid form.
• Cediranib is not a cytotoxic agent; its primary action is anti-proliferative via angiogenesis inhibition, not direct tumor cell killing.
• Not all tumor types are VEGFR-dependent; efficacy may be limited in tumors lacking angiogenic drive.

Workflow Integration & Parameters

Cediranib (A1882) from APExBIO is provided as a solid powder (MW 450.51, C₂₅H₂₇FN₄O₃), recommended for DMSO dissolution at ≥22.52 mg/mL and storage at -20°C (product page). For in vitro kinase assays, working concentrations range from 0.1 nM to 1 μM, depending on target selectivity and cell model. For cell signaling studies, 1–50 nM is typical for VEGFR pathway inhibition. Solutions should be freshly prepared; avoid repeated freeze-thaw cycles. In PI3K/Akt/mTOR pathway studies, Cediranib’s effect on Akt phosphorylation is measurable by Western blot within 30–60 minutes post-addition.

For troubleshooting and advanced in vitro modeling protocols, "Cediranib: Precision VEGFR Tyrosine Kinase Inhibition in ..." offers detailed workflow guidance; this article updates the recommended storage and solubility parameters for optimal experimental reproducibility.

Conclusion & Outlook

Cediranib (AZD2171) remains a gold-standard ATP-competitive VEGFR tyrosine kinase inhibitor for angiogenesis research and PI3K/Akt/mTOR pathway studies. Its sub-nanomolar potency, multi-target profile, and compatibility with advanced in vitro models support its ongoing use in translational oncology and drug development. APExBIO provides Cediranib (A1882) as a rigorously characterized, workflow-ready reagent. Future research may expand its use in combination therapies and complex 3D tumor modeling, but careful attention to solubility, storage, and off-target effects is required for reproducible results.